ArticleAsian Pacific journal of cancer prevention : APJCP2025
Epidemiology of Thyroid Cancer in Kazakhstan and in Areas Adjacent to the Former Semipalatinsk Nuclear Test Site in 2013-2023.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Consumer Perception of Irradiated Food Products in the Abai Region of Kazakhstan.Foods (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the incidence and mortality of thyroid cancer (TC) in the Republic of Kazakhstan and East Kazakhstan Region, which includes the areas adjacent to the former Semipalatinsk nuclear test site over the past ten years, from 2013 to 2023.
methodsThe study included information from Form No. 7 Annual "Report on Patients with Malignant Neoplasms" and "Indicators of the Oncological Service of the Republic of Kazakhstan" for the period 2013-2023. Incidence and mortality rates were calculated per 100,000 population, and data were distributed by gender, age groups, clinical stages. The study included an analysis of trends in annual epidemiological indicators, which allows us to observe fluctuations in Incidence and mortality over time.
resultsOverall, Republic of Kazakstan experienced a gradual increase in incidence, beginning at 2.9 per 100,000 population in 2013, peaking at 7.2 in 2019, and ending at 5.5 in 2023. East Kazakhstan, however, showed greater fluctuation, with rates ranging from 3.2 to 4.3 per 100,000, with a notable increase in 2023 to 4.7 per 100,000 population, the highest value observed in the study period. In East Kazakhstan, mortality remained steady at 0.4 per 100,000 from 2013 to 2016, briefly increasing to 0.9 in 2018, before stabilizing at 0.4 from 2020 to 2023. Nationwide, TC mortality varied between 0.3 and 0.5 per 100,000, with a gradual decline to 0.3 per 100,000 in 2021 and 2023.
conclusionIn the areas adjacent to the former Semipalatinsk nuclear test site, significant fluctuations and peaks in morbidity are observed, which differ from the general republican indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.